[ad_1]
STOCKHOLM, Jan. 20, 2022 /PRNewswire/ — NeoDynamics AB (Spotlight Stock Market: NEOD), a medtech company dedicated to advancing diagnosis and care of breast cancer, will present results from the PULSE study illustrating the benefits of the novel biopsy device NeoNavia in challenging axillary lymph nodes, at the SBI/ACR Breast Imaging Symposium in Savannah, Georgia, taking place on May 16-19. The symposium is held to be the most important annual meeting for US breast imaging professionals.
A subgroup analysis from the ethically approved German prospective multi-center study PULSE (ClinicalTrials.gov ID: NCT03975855), shows that the biopsy device NeoNavia was safe and effective for percutaneous tissue sampling also in axillary lymph nodes presenting parameters indicating high anatomic complexity and procedural difficulty. The system’s pulses were perceived to stabilize the target lesion and provide needle control during insertion. It was also possible to obtain multiple samples with a single insertion.
The scientific abstract has been accepted for oral presentation at the symposium. The presentation will be carried out by the Principial Investigator, Prof. Marc Thill, AGAPLESION MARKUS KRANKENHAUS Frankfurt, under the title “New pulse biopsy device safe and effective in challenging cases of axillary biopsies: Subgroup analysis of initial PULSE data for lymph nodes of small size and difficult anatomic location”.
“The NeoNavia device has demonstrated great performance in the most challenging subgroup of cases in the PULSE study. Management of the axilla …
Full story available on Benzinga.com
[ad_2]
Source link
